Company Analysis

AbCellera Biologics Inc. (ABCL)

Nasdaq: ABCL · Pharmaceutical Preparations · Vancouver, BC · filing with the SEC since 2017
Grade5.8
◀ Past 6.7● Present 5.7▶ Future 5.0
1 est.

Who runs AbCellera Biologics Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Hansen Carl L. G.
Chief Executive Officer. First filing Dec 2020, latest Jan 5, 2026, 1 filing in all.
Officers reporting now
4
of 9 people with a filing in the last fifteen months
Directors reporting now
5
13 people on the record since 2020
Officerssales are open-market, Nov 12, 2025 to Nov 12, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Booth AndrewChief Financial OfficerDec 2020Aug 14, 2026none
Hansen Carl L. G.Chief Executive OfficerDec 2020Jan 5, 2026none
Lecault VeroniqueChief Technology OfficerDec 2020Jan 5, 2026none
Stimart TrynChief Legal OfficerDec 2020Jan 5, 2026none
Directorssales are open-market, Nov 12, 2025 to Nov 12, 2026
NameRoleFirst filingLatest filingSales, 12 months
Hayden Michael RdirectorNov 2020Aug 24, 2026none
Montalbano John S.directorDec 2020Aug 18, 2026none
Sandor VictordirectorJun 2026Jul 6, 2026none
Seely LynndirectorJul 2026Jul 6, 2026none
Quake StephendirectorDec 2025Jun 12, 2026none
Owners of more than 10% of a classsales are open-market, Nov 12, 2025 to Nov 12, 2026
NameRoleFirst filingLatest filingSales, 12 months
Thermopylae Holdings Ltd.10% ownerDec 2020Nov 12, 2026none
Earlier names on the record11, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton ABCL · research, not advice